<div id="readability-page-1"><div><p><span>Pfizer </span><span> said on Tuesday its experimental obesity drug, which it acquired through the Metsera deal, showed up to 12.3% weight loss in patients without diabetes in a mid-stage trial.</span></p></div></div>

<p>Pfizer said on Tuesday its experimental obesity drug, which it acquired through the Metsera deal, showed up to 12.3% weight loss in patients without diabetes in a mid-stage trial.</p>

Reuters

iShares Global Healthcare

Pfizer

First Trust NYSE Arca Biotech Index Fd

Invesco Biotechnology & Genome ETF

SPDR S&P Biotech

ALPS Medical Breakthrough

Invesco Nasdaq Biotechnology ETF

VG Health

iShares US Pharma

iShares Biotechnology ETF

Proshares Ultra Nasdaq Biotech

Ark Genomic Revolution ETF

Health Care Select Sector SPDR

Pfizer's experimental drug shows up to 12.3% weight loss in mid-stage trial